The annual meeting of CTOS (Connective Tissue Oncology Society) will be held virtually this year due to the global pandemic.
CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues. The goal of the society is to advance the care of patients with connective tissue tumors and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research.
The Life Raft Group is a member of CTOS and has attended this conference every year since the early days of our organization. We are proud to be participating this year in both a poster presentation and in a panel discussion. Spearheaded by LRG’s Data Analyst Jerry Call and in collaboration with Dr. Jonathan Trent, we have submitted this poster:
Poster #058 3455149
(GIST) PATIENTS WITH KNOWN MUTATION TRANSITION TO SUBSEQUENT TREATMENTS AT A HIGHER RATE AND HAVE SUPERIOR SURVIVAL COMPARED TO PATIENTS WITHOUT KNOWN MUTATION: RESULTS FROM THE LIFERAFT GROUP (LRG) GIST REGISTRY.
According to Jerry Call this study calls attention to the disparity in treatment, even among highly proactive patients. It sheds light on the fact that patients who receive mutational testing receive more treatment leading to better outcomes.
Vice President, Program Services, Sara Rothschild, will be part of a panel discussion entitled “Meet the Experts”, where several challenging GIST cases will be presented by Dr. Maria Pantaleo to the multidisciplinary panel. Moderated by Dr. William Tap, the panel will take place on Thursday, November 19th, from 1:30 – 2:30 PM (ET).
The Life Raft Group continues to be a part of key organizations and participates in collaborative relationships in order to be on the forefront of new and innovative initiatives that impact the treatment of GIST patients.
